Effects of Taxane-induced Peripheral Neuropathy on Hand Dexterity Impairment: Evaluation of Quantitative and Subjective Assessments

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2024 Apr 23

PMID 38652168

Authors

Masahiro Manfuku

Junichiro Inoue

Nobuki Yamanaka

Hiroe Kanamori

Kazuhiro Sumiyoshi

Michihiro Osumi

Affiliations

Soon will be listed here.

Abstract

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) commonly involves hand dexterity impairment. However, the factors affecting hand dexterity impairment are unknown and there is currently no established treatment. The purpose of the current study was to clarify factors influencing hand dexterity impairment in taxane-induced peripheral neuropathy using subjective and objective assessments.

Methods: We assessed patient characteristics, treatment-related factors, subjective symptoms of CIPN (Patient Neurotoxicity Questionnaire [PNQ]), psychological symptoms, and upper limb dysfunction (Quick Disabilities of the Arm, Shoulder and Hand [Quick DASH]). Quantitative assessments were pinch strength, sensory threshold, hand dexterity impairment, and grip force control. Multiple regression analysis was performed using hand dexterity impairment as the dependent variable and age and PNQ, Quick DASH, and control of grip force as independent variables.

Results: Forty-three breast cancer patients were included in the analysis. Hand dexterity impairment in taxane-induced peripheral neuropathy patients was significantly correlated with age, grip force control, and PNQ sensory scores (p < 0.008). Multiple regression analysis demonstrated that PNQ sensory scores and grip force control were significantly associated with hand dexterity impairment (p < 0.01).

Conclusion: Subjective symptoms (numbness and pain) and grip force control contributed to impaired hand dexterity in taxane-induced peripheral neuropathy.

References

Flatters S, Dougherty P, Colvin L . Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth. 2017; 119(4):737-749. DOI: 10.1093/bja/aex229. View

Park S, Goldstein D, Krishnan A, Lin C, Friedlander M, Cassidy J . Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2014; 63(6):419-37. DOI: 10.3322/caac.21204. View

Seretny M, Currie G, Sena E, Ramnarine S, Grant R, Macleod M . Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155(12):2461-2470. DOI: 10.1016/j.pain.2014.09.020. View

Rivera D, Ganz P, Weyrich M, Bandos H, Melnikow J . Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. J Natl Cancer Inst. 2017; 110(2). PMC: 5825681. DOI: 10.1093/jnci/djx140. View

Osumi M, Sumitani M, Abe H, Otake Y, Kumagaya S, Morioka S . Kinematic evaluation for impairment of skilled hand function in chemotherapy-induced peripheral neuropathy. J Hand Ther. 2017; 32(1):41-47. DOI: 10.1016/j.jht.2017.06.003. View

Zanville N, Nudelman K, Smith D, Von Ah D, McDonald B, Champion V . Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer. 2016; 24(11):4779-89. PMC: 5031751. DOI: 10.1007/s00520-016-3329-5. View

Bakitas M . Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007; 56(5):323-31. DOI: 10.1097/01.NNR.0000289503.22414.79. View

Tugral A, Aribas Z, Akyol M, Bakar Y . Assessment of sensorimotor and strength related function of breast cancer patients during systemic drug therapy: a prospective observational study. BMC Cancer. 2023; 23(1):981. PMC: 10576361. DOI: 10.1186/s12885-023-11494-x. View

McCrary J, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan M . Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer. 2017; 25(11):3485-3493. DOI: 10.1007/s00520-017-3772-y. View

10.

Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I . Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Support Care Cancer. 2023; 31(5):293. PMC: 11552664. DOI: 10.1007/s00520-023-07734-2. View

11.

Guo S, Han W, Wang P, Wang X, Fang X . Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis. J Cancer Surviv. 2022; 17(2):318-331. DOI: 10.1007/s11764-022-01182-3. View

12.

Tamburin S, Park S, Schenone A, Mantovani E, Hamedani M, Alberti P . Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2021; 171:103575. PMC: 10658987. DOI: 10.1016/j.critrevonc.2021.103575. View

13.

Vanbellingen T, Nyffeler T, Nigg J, Janssens J, Hoppe J, Nef T . Home based training for dexterity in Parkinson's disease: A randomized controlled trial. Parkinsonism Relat Disord. 2017; 41:92-98. DOI: 10.1016/j.parkreldis.2017.05.021. View

14.

Che Bakri N, Kwasnicki R, Khan N, Ghandour O, Lee A, Grant Y . Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg. 2022; 277(4):572-580. PMC: 9994843. DOI: 10.1097/SLA.0000000000005671. View

15.

Leysen L, Beckwee D, Nijs J, Pas R, Bilterys T, Vermeir S . Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2017; 25(12):3607-3643. DOI: 10.1007/s00520-017-3824-3. View

16.

Hausheer F, Schilsky R, Bain S, Berghorn E, Lieberman F . Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1):15-49. DOI: 10.1053/j.seminoncol.2005.12.010. View

17.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K . Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17(12):1483-91. DOI: 10.1007/s00520-009-0613-7. View

18.

Kennedy C, Beaton D, Smith P, Van Eerd D, Tang K, Inrig T . Measurement properties of the QuickDASH (disabilities of the arm, shoulder and hand) outcome measure and cross-cultural adaptations of the QuickDASH: a systematic review. Qual Life Res. 2013; 22(9):2509-47. DOI: 10.1007/s11136-013-0362-4. View

19.

Staples L, Dear B, Gandy M, Fogliati V, Fogliati R, Karin E . Psychometric properties and clinical utility of brief measures of depression, anxiety, and general distress: The PHQ-2, GAD-2, and K-6. Gen Hosp Psychiatry. 2018; 56:13-18. DOI: 10.1016/j.genhosppsych.2018.11.003. View

20.

Raji P, Nakhostin Ansari N, Naghdi S, Forogh B, Hasson S . Relationship between Semmes-Weinstein Monofilaments perception Test and sensory nerve conduction studies in Carpal Tunnel Syndrome. NeuroRehabilitation. 2014; 35(3):543-52. DOI: 10.3233/NRE-141150. View